» Articles » PMID: 21267990

Recurrence-free Survival More Than 10 Years After Liver Resection for Hepatocellular Carcinoma

Overview
Journal Br J Surg
Specialty General Surgery
Date 2011 Jan 27
PMID 21267990
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Background: High recurrence rates after liver resection with curative intent for hepatocellular carcinoma (HCC) remain a problem. The characterization of long-term survivors without recurrence after liver resection may help improve the therapeutic strategy for HCC.

Methods: A nationwide Japanese database was used to analyse 20 811 patients with HCC who underwent liver resection with curative intent.

Results: The 10-year recurrence-free survival rate after liver resection for HCC with curative intent was 22.4 per cent. Some 281 patients were recurrence-free after more than 10 years. The HCCs measured less than 5 cm in 83.2 per cent, a single lesion was present in 91.7 per cent, and a simple nodular macroscopic appearance was found in 73.3 per cent of these patients; histologically, most HCCs showed no vascular invasion or intrahepatic metastases. Multivariable analysis revealed tumour differentiation as the strongest predictor of death from recurrent HCC within 5 years.

Conclusion: Long-term recurrence-free survival is possible after liver resection for HCC, particularly in patients with a single lesion measuring less than 5 cm with a simple nodular appearance and low tumour marker levels.

Citing Articles

[Multiparametric magnetic resonance imaging for hepatocellular carcinoma, part 1 : Morphology and dynamic perfusion imaging in primary diagnostics and treatment monitoring].

Jahn M, Layer G Radiologie (Heidelb). 2024; 64(4):321-332.

PMID: 38502373 DOI: 10.1007/s00117-024-01285-1.


A robust panel based on genomic methylation sites for recurrence-free survival in early hepatocellular carcinoma.

Long G, Zhao L, Tang B, Zhou L, Mi X, Su W Heliyon. 2023; 9(9):e19434.

PMID: 37809660 PMC: 10558510. DOI: 10.1016/j.heliyon.2023.e19434.


Analysis of TRIM27 prognosis value and immune infiltrates in hepatocellular carcinoma.

Wang H, Zhang Y, Yan L, Lv Q, Lu J, Yun B Int J Immunopathol Pharmacol. 2022; 36:3946320221132986.

PMID: 36217828 PMC: 9558858. DOI: 10.1177/03946320221132986.


Long-term outcomes of ablation, liver resection, and liver transplant as first-line treatment for solitary HCC of 3 cm or less using an intention-to-treat analysis: A retrospective cohort study.

Ivanics T, Rajendran L, Abreu P, Claasen M, Shwaartz C, Patel M Ann Med Surg (Lond). 2022; 77:103645.

PMID: 35637985 PMC: 9142643. DOI: 10.1016/j.amsu.2022.103645.


[Resection and transplantation for hepatocellular carcinoma and intrahepatic cholangiocarcinoma].

Seehofer D, Sucher R, Denecke T Radiologe. 2022; 62(3):210-218.

PMID: 35080635 DOI: 10.1007/s00117-021-00962-9.